Список литературы к Главе 13

61. Bologna L. et al. Mechanism of action of type II, glycoengineered, anti­CD20 monoclonal antibody GA101 in B­chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab // J. Immunol. 2011. Vol. 186, N 6. P. 3762–3769.

62. Rafiq S. et al. Comparative assessment of clinically utilized CD20­directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties // J. Immunol. 2013. Vol. 190, N 6. P. 2702–2711.

63. Kohrt H.E. et al. Ibrutinib antagonizes rituximab­dependent NK cell­mediated cytotoxicity // Blood. 2014. Vol. 123, N 12. P. 1957–1960.

64. Khurana D. et al. Differential regulation of human NK cell­mediated cytotoxicity by the tyrosine kinase Itk // J. Immunol. 2007. Vol. 178, N 6. P. 3575–3582.

65. Fabio Da R. et al. Ibrutinib interferes with the cell­mediated anti­tumor activities of therapeutic CD20 antibodies: implications for combination therapy // Haematologica. 2015. Vol. 100, N 1. P. 77–86.

66. Golay J., Greta U., Martino I. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP­196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies // Haematologica. 2017. Vol. 102, N 10. P. e400–e403.

67. Borge M. et al. Ibrutinib impairs the phagocytosis of rituximab­coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages // Haematologica. 2015. Vol. 100, N 4. P. e140–e142.

68. VanDerMeid K.R. et al. Cellular cytotoxicity of next­generation CD20 monoclonal antibodies // Cancer Immunol. Res. 2018. Vol. 6, N 10. P. 1150.

69. de Rooij M.F. et al. The clinically active BTK inhibitor PCI­32765 targets B­cell receptor­ and chemokine­controlled adhesion and migration in chronic lymphocytic leukemia // Blood. 2012. Vol. 119, N 11. P. 2590–2594.

70. Herman S.E. et al. Ibrutinib­induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study // Leukemia. 2014. Vol. 28, N 11. P. 2188–2196.

71. von Tresckow J. et al. CLL2­BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia // Leukemia. 2019. Vol. 33, N 5. P. 1161–1172.

72. Cramer P., von Tresckow J., Robrecht S., Bahlo J., Al­Sawaf O., Langerbeins P. et al. Bendamustine followed by ofatumumab and ibrutinib in patients with chronic lymphocytic leukemia (CLL): CLL2­BIO trial of the German CLL Study Group (GCLLSG) // Blood. 2017. Vol. 130. P. S494–S1494.

73. Woyach J.A. et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy // Blood. 2014. Vol. 123, N 12. P. 1810–1817.

74. Hallek M. et al. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia // Future Oncol. 2015. Vol. 11, N 1. P. 51–59.

75. Jones J.A. et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single­agent ibrutinib // Br. J. Haematol. 2017. Vol. 178, N 2. P. 286–291.

76. Dmitrieva E.A. et al. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib // J. Thromb. Haemost. 2020. Vol. 18, N 10. P. 2672–2684.

77. Bye A.P. et al. Ibrutinib inhibits platelet integrin alphaIIbbeta3 outside­in signaling and thrombus stability but not adhesion to collagen // Arterioscler. Thromb. Vasc. Biol. 2015. Vol. 35, N 11. P. 2326–2335.

78. Levade M. et al. Targeting kinases in cancer therapies: adverse effects on blood platelets // Curr. Pharm. Des. 2016. Vol. 22, N 16. P. 2315–2322.

79. Kamel S. et al. Ibrutinib inhibits collagen­mediated but not ADP­mediated platelet aggregation // Leukemia. 2015. Vol. 29, N 4. P. 783–787.

80. Kazianka L. et al. Ristocetin­induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib // Leukemia. 2017. Vol. 31, N 5. P. 1117–1122.

81. Lipsky A.H., Lozier J.N., Wiestner A. Response to comment on incidence and risk factors of bleeding­related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib // Haematologica. 2016. Vol. 101, N 3. P. e124–e125.

82. Pulte D. et al. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia // J. Transl. Med. 2007. Vol. 5. P. 23.

83. Series J. et al. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions // Haematologica. 2019. Vol. 104, N 11. P. 2292–2299.

84. Mozaffarian D. et al. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association // Circulation. 2015. Vol. 131, N 4. P. e29–e322.

85. Leong D.P. et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta­analysis // Blood. 2016. Vol. 128, N 1. P. 138–140.

86. Tang C.P.S., McMullen J., Tam C. Cardiac side effects of Bruton tyrosine kinase (BTK) inhibitors // Leuk. Lymphoma. 2018. Vol. 59, N 7. P. 1554–1564.

87. Brown J.R. et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials // Haematologica. 2017. Vol. 102, N 10. P. 1796–1805.

88. Thompson P.A. et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study // Br. J. Haematol. 2016. Vol. 175, N 3. P. 462–466.

89. Maddocks K., Jones J.A. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia // Semin. Oncol. 2016. Vol. 43, N 2. P. 251–259.

90. Fauchier L. et al. Causes of death and influencing factors in patients with atrial fibrillation // Am. J. Med. 2016. Vol. 129, N 12. P. 1278–1287.

91. McMullen J.R. et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K­Akt signaling // Blood. 2014. Vol. 124, N 25. P. 3829–3830.

92. Pretorius L. et al. Reduced phosphoinositide 3­kinase (p110alpha) activation increases the susceptibility to atrial fibrillation // Am. J. Pathol. 2009. Vol. 175, N 3. P. 998–1009.

93. Lampson B.L. et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib // Blood. 2017. Vol. 129, N 18. P. 2581–2584.

94. Mato A.R. et al. Ibrutinib­induced pneumonitis in patients with chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 8. P. 1064–1067.

95. Woyach J.A. et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib // N. Engl. J. Med. 2014. Vol. 370, N 24. P. 2286–2294.

96. Woyach J.A. et al. BTK(C481S)­mediated resistance to ibrutinib in chronic lymphocytic leukemia // J. Clin. Oncol. 2017. Vol. 35, N 13. P. 1437–1443.

97. Ahn I.E. et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia // Blood. 2017. Vol. 129, N 11. P. 1469–1479.

98. Burger J.A. et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition // Nat. Commun. 2016. Vol. 7. Article ID 11589.

99. Kanagal­Shamanna R. et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor­resistant chronic lymphocytic leukemia with disease progression and Richter transformation // Cancer. 2019. Vol. 125, N 4. P. 559–574.

100. Ликольд Е.Б., Февралева И.С., Бидерман Б.В., Дмитриева Е.А., Никитин Е.А., Судариков А.Б. Выявление мутации Cys481Ser в гене BTK методом АС­ПЦР у пациентов с ХЛЛ при лечении ибрутинибом // Гематология и трансфузиология. 2020. Т. 65, № S1. С. 82–83.

101. Albitar A. et al. Using high­sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell­free DNA and correlation with progression in patients treated with BTK inhibitors // Oncotarget. 2017. Vol. 8, N 11. P. 11 936–11 944.

102. Barf T. et al. Acalabrutinib (ACP­196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile // J. Pharmacol. Exp. Ther. 2017. Vol. 363, N 2. P. 240–252.

103. Byrd J.C. et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results // Blood. 2020. Vol. 135, N 15. P. 1204–1213.

104. Ghia P. et al. Acalabrutinib vs rituximab plus idelalisib (IdR) or bendamustine (BR) by investigator choice in relapsed/refractory (RR) chronic lymphocytic leukemia: phase 3 ASCEND study // Hematol. Oncol. 2019. Vol. 37, N S2. P. 86–87.

105. Sharman J.P. et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment­naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial // Lancet. 2020. Vol. 395, N 10 232. P. 1278–1291.

106. Covey T. et al. Pharmacodynamic evaluation of acalabrutinib in relapsed/refractory and treatment­naive patients with chronic lymphocytic leukemia (CLL) in the phase 1/2 ACE­CL­001 study // Blood. 2017. Vol. 130, suppl. 1. P. 1741.

107. Patel V. et al. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells // Clin. Cancer Res. 2017. Vol. 23, N 14. P. 3734–3743.

108. Lampson B.L. et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL) // Blood. 2019. Vol. 134, suppl. 1. P. 32.

109. Parikh S.A. et al. A randomized phase 2 study comparing acalabrutinib with or without obinutuzumab in the treatment of early stage high risk patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) // Blood. 2019. Vol. 134, suppl. 1. P. 4306.

110. Patel V.K. et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on­target effects to ibrutinib and rationale for combination therapy // Leukemia. 2018. Vol. 32, N 4. P. 920–930.

111. Awan F.T. et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who areintolerant to ibrutinib // Blood Adv. 2019. Vol. 3, N 9. P. 1553–1562.